CHMP Adopts Positive Opinion for BMS’s Abecma in ≥4L r/r MM

On Friday, June 25, the CHMP adopted (press release) a positive opinion for Abecma (idecabtagene vicleucel; BCMA CAR-T) in ≥4L relapsed/refractory multiple myeloma (MM). The Celltelligence team will provide a detailed analysis in the coming days about Abecma’s positive CHMP opinion and BMS’s potential launch strategy within Europe.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.